KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04 2025 - 6:00AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted fifty-two newly-hired employees inducement options to
purchase an aggregate of 261,000 shares of KalVista common stock on
February 3, 2025 as inducements material to each employee entering
into employment with KalVista. The options have an exercise price
that is equal to the closing price of KalVista common stock on the
grant date.
One-fourth of the options vest on the one-year anniversary of
the vesting commencement date and the remainder vest in equal
monthly installments over the next three years, in each case
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term and is subject to the terms
and conditions of KalVista’s Inducement Equity Incentive Plan and a
stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule
5635(c)(4).
About KalVista Pharmaceuticals, Inc. KalVista
Pharmaceuticals, Inc., is a global biopharmaceutical company
dedicated to developing and delivering life-changing oral therapies
for individuals affected by rare diseases with significant unmet
needs. Our lead investigational product is sebetralstat, a novel,
oral, on-demand treatment for hereditary angioedema (HAE).
Sebetralstat is under regulatory review by the U.S. FDA, with a
PDUFA goal date of June 17, 2025. In addition, we have completed
Marketing Authorization Applications for sebetralstat to the
European Medicines Agency and multiple other global regulatory
authorities.
For more information about KalVista, please visit
www.kalvista.com or follow on social media at @KalVista and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250204778137/en/
KalVista Pharmaceuticals, Inc. Media: Jenn Snyder
Vice President, Corporate Affairs (857) 356-0479
jennifer.snyder@kalvista.com
Investors: Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Jan 2025 to Feb 2025
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Feb 2024 to Feb 2025
